Lunai Bioworks Inks Parkinson's Collaboration with BrainStorm, Targets 2027 Data Readout
LNAI has more than doubled off its 52-week low of $1.21 on light trading volume (0.2× avg).
Summary
Lunai Bioworks signed a definitive Master Collaboration Agreement with BrainStorm Therapeutics to advance AI-driven Parkinson's disease research. The deal combines Lunai's Contingent AI patient-stratification platform with BrainStorm's human brain organoid models. A new white paper from subsidiary BioSymetrics identifies clinically distinct Parkinson's subtypes, providing a foundation for biomarker and target discovery. The companies target an initial data readout in the first half of 2027. This follows Lunai's recent Nasdaq compliance recovery and first defense contract, marking a strategic pivot toward neuroscience partnerships. The collaboration opens near-term pharma partnering opportunities for clinical trial optimization, with longer-term potential for biomarker panels and therapeutic programs. For a micro-cap company with a going concern warning, a credible partnership with an award-winning platform adds tangible pipeline value.
At the time of this announcement, LNAI was trading at $2.54 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $11.5M. The 52-week trading range was $1.21 to $21.58. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: PR Newswire.